SEOM clinical guidelines for anaplastic gliomas (2017)
- PMID: 29058264
- PMCID: PMC5785606
- DOI: 10.1007/s12094-017-1762-7
SEOM clinical guidelines for anaplastic gliomas (2017)
Erratum in
-
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017).Clin Transl Oncol. 2018 Jul;20(7):937. doi: 10.1007/s12094-018-1904-6. Clin Transl Oncol. 2018. PMID: 29858734 Free PMC article.
Abstract
The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with slight modifications according to molecular variables. A multidisciplinary team is highly recommended in the management of these tumors.
Keywords: Anaplastic astrocytoma; Anaplastic glioma; Anaplastic oligodendroglioma.
Conflict of interest statement
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
